Welcome to our dedicated page for Invivyd SEC filings (Ticker: IVVD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Invivyd, Inc. filings document material events, governance matters, capital actions, and financial-result disclosures for a Nasdaq-listed biopharmaceutical company developing monoclonal antibodies for serious viral infectious diseases. Recent Form 8-K reports furnish operating results, preliminary product revenue information for PEMGARDA, corporate presentations, and program updates involving COVID-19, RSV, and measles antibody candidates.
The filing record also includes a definitive proxy statement covering annual-meeting matters such as director elections and auditor ratification, as well as an 8-K describing a completed underwritten public offering of common stock and pre-funded warrants. These disclosures describe the company’s common stock, financing activity, board governance, research and development priorities, and commercial preparedness around its antibody portfolio.
Invivyd, Inc. (symbol IVVD) filed a notice of proposed sale of 40,800 shares of common stock under Form 144. The shares are to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services, with sales expected to occur on or after August 17, 2026 on Nasdaq.
The seller’s shares were acquired as equity compensation: on August 15, 2026, 102,000 shares of common stock were acquired upon vesting of restricted stock units granted under the company’s 2021 Equity Incentive Plan. This filing serves as advance notice of the contemplated resale by an affiliate or holder subject to Rule 144.
In vivodyne, Inc. (symbol IVVD) reported a planned sale of its common stock by an affiliated brokerage account. A Morgan Stanley Smith Barney LLC Executive Financial Services account intends to sell up to 40,800 shares of common stock on 08/17/2026 through Nasdaq.
The securities to be sold were acquired as equity compensation, specifically common stock received upon vesting of 102,000 restricted stock units granted under the issuer’s 2021 Equity Incentive Plan on 08/15/2026. This notice describes a potential resale by the holder rather than a new issuance by the company.
Invivyd Inc. (symbol IVVD) reported a planned sale of 68,001 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services at Nasdaq, with an indicated aggregate market value of $49,021.92. The shares relate to common stock acquired upon vesting of restricted stock units under Invivyd’s 2021 Equity Incentive Plan, with 170,000 shares acquired on August 15, 2026. The planned sale date listed is August 17, 2026, and the filing also notes a total common stock figure of 294,758,746 shares, which serves as a reference baseline.
Invivyd Inc. filed a notice of proposed sale of 37,741 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services, with the shares listed on Nasdaq and a stated aggregate market value of 27,207.49. The notice references 294,758,746 shares of common stock outstanding. The securities to be sold include common stock acquired on August 15, 2026 upon vesting of restricted stock units granted under Invivyd’s 2021 Equity Incentive Plan, with 102,000 shares shown as acquired on that date as equity compensation.
Perceptive Advisors LLC, Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd. report beneficial ownership of INVIVYD, INC. common stock. The Master Fund directly holds 18,490,636 shares of common stock, while Perceptive Advisors, as investment manager, and Mr. Edelman, as managing member of Perceptive Advisors, report indirect beneficial ownership.
The filing states this position represents 6.3% of INVIVYD’s common stock for each reporting person, based on 294,758,746 shares outstanding as of July 30, 2026. All three reporting persons have shared voting and dispositive power over 18,490,636 shares and no sole voting or dispositive power.
Invivyd, Inc. has a significant shareholder group led by Biotechnology Value Fund entities and Mark N. Lampert, which collectively may be deemed to beneficially own 29,571,826 shares of common stock, including shares underlying pre-funded warrants, representing approximately 9.99% of the outstanding class as of June 30, 2026.
The group holds Pre-Funded Warrants exercisable for an aggregate 6,000,000 shares at an exercise price of $0.0001 per share, subject to a 9.99% beneficial ownership blocker. Due to this blocker, only 1,406,826 of those underlying shares are currently counted toward beneficial ownership. The percentage calculations use 294,607,452 shares outstanding as of April 30, 2026, plus the currently exercisable warrant shares.
Invivyd, Inc. reports that for the six months ended June 30, 2026 it generated $28.0 million in net product revenue, up from $23.1 million a year earlier, driven by sales of PEMGARDA. However, total operating costs and expenses rose to $117.0 million, leading to a net loss of $85.8 million versus $30.9 million in the prior-year period.
Cash and cash equivalents were $160.1 million at June 30, 2026, down from $226.7 million at December 31, 2025, after $84.7 million of net cash used in operating activities in the first half. Stockholders’ equity declined to $181.1 million from $241.5 million, and the accumulated deficit reached $1,040.3 million. Management states there is substantial doubt about the company’s ability to continue as a going concern because existing cash is not expected to fund operations beyond one year without additional financing.
PEMGARDA holds U.S. FDA emergency use authorization for pre-exposure prophylaxis of COVID-19, but the EUA is set to terminate on June 29, 2027 following a declared transition period. Invivyd is advancing VYD2311, a next-generation COVID-19 monoclonal antibody, through Phase 3 clinical trials (DECLARATION and LIBERTY) with top-line data planned later in the third quarter of 2026, and is progressing RSV and measles antibody candidates toward IND readiness.
Invivyd, Inc. reported second quarter 2026 PEMGARDA net product revenue of $14.3 million, up 21% from $11.8 million in Q2 2025, driven by increased patient demand. Cash and cash equivalents were $160.1 million as of June 30, 2026, which the company anticipates will fund operations through the DECLARATION pivotal data readout and potential VYD2311 launch readiness.
R&D expenses rose to $29.4 million from $9.6 million, and SG&A expenses increased to $29.5 million from $16.6 million, contributing to a wider net loss of $44.4 million versus $14.7 million a year earlier. Enrollment in the pivotal DECLARATION and Phase 3 LIBERTY VYD2311 trials is complete, with top-line data expected in late Q3 2026. Invivyd is also advancing VMS063 for measles and VBY329 for RSV, while PEMGARDA remains under EUA with a 12‑month termination notice issued in July 2026.
Invivyd, Inc. granted Chief Medical Officer and Chief Epidemiologist Michael Mina a stock option for 1,125,000 shares of common stock, with an exercise price of $0.535 per share and expiration on July 30, 2036. The option vests over four years: 25% on July 31, 2027, and the remaining 75% in substantially equal monthly installments (1/48 of the total) over the following three years, subject to his continuous service.
Invivyd, Inc. reports that CMO and Chief Epidemiologist Mina Michael beneficially holds a stock option to purchase 375,000 shares of common stock at an exercise price of $1.33 per share, expiring on March 31, 2036. The option vests over four years, with 25% vesting on March 5, 2027 and the remaining 75% vesting in substantially equal monthly installments over the following three years, subject to continuous service.